Skip to main content

Table 2 Patterns of Large Vessel Occlusions comparing patients with DOAC and VKA pretreatment

From: MRI characteristics in acute ischemic stroke patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists

 DOAC pretreatment (N = 75)VKA pretreatment (N = 61)PConfirmed therapeutic DOAC (N = 35)Confirmed therapeutic VKA (N = 45)P
Any large vessel occlusion22/75 (29.3%)23/61 (37.7%)0.3619/35 (25.7%)14/45 (31.1%)0.628
- Proximal ICA1 (4.5%)1 (4.3%) 00 
- Carotid-T2 (9.1%)2 (8.7%) 1 (11.1%)1 (7.1%) 
- Proximal M17 (31.8%)4 (17.4%) 3 (33.3%)1 (7.1%) 
- Distal M13 (13.6%)1 (4.3%) 1 (11.1%)1 (7.1%) 
- M26 (27.3%)6 (26.1%) 3 (33.3%)4 (28.6%) 
- M301 (4.3%) 01 (7.1%) 
- A100 00 
- A21 (4.5%)0 00 
- V401 (4.3%) 01 (7.1%) 
- BA00 00 
- P101 (4.3%) 01 (7.1%) 
- P2/31 (4.5%)4 (17.4%) 04 (28.6%) 
- Multiple1 (4.5%)1 (4.3%) 1 (11.1%)0 
- SCA01 (4.3%) 00 
Potential target large vessel occlusion for EVT20/75 (26.7%)17/61 (27.9%)1.0009/35 (25.7%)9/45 (20.0%)0.596
  1. DOAC Direct oral anticoagulant, VKA Vitamin K antagonist, ICA Internal carotid artery, M1 M1-segment of medial cerebral artery, M2 M2-segment of medial cerebral artery, M3 M3-segment of medial cerebral artery, A1 A1-segment of anterior cerebral artery, A2 A2-segment of anterior cerebral artery, V4 V4-segment of vertebral artery, BA Basilar artery, P1 P1-segment of posterior cerebral artery, P2/3 P2 or P3-segment of posterior cerebral artery, SCA Superior cerebellar artery, EVT Endovascular stroke treatment